Copyright
©The Author(s) 2020.
World J Clin Cases. Jun 6, 2020; 8(11): 2255-2265
Published online Jun 6, 2020. doi: 10.12998/wjcc.v8.i11.2255
Published online Jun 6, 2020. doi: 10.12998/wjcc.v8.i11.2255
Figure 1 Serum levels of cytokines in chronic hepatitis B patients according to treatment phases and responses to peginterferon α-2a.
A: CXC-chemokine ligand 9; B: Interferon gamma-induced protein 10; C: Macrophge inhibitory protein-1 delta; D: Thymus and activation-regulated chemokine. VRs: Virological responders, NRs: Non-virological responders; CXCL9: CXC-chemokine ligand 9; IP10: Interferon gamma-induced protein 10; MIP-1d: Macrophge inhibitory protein-1 delta; TARC: Thymus and activation-regulated chemokine.
- Citation: Fu WK, Cao J, Mi NN, Huang CF, Gao L, Zhang JD, Yue P, Bai B, Lin YY, Meng WB. Cytokines predict virological response in chronic hepatitis B patients receiving peginterferon alfa-2a therapy. World J Clin Cases 2020; 8(11): 2255-2265
- URL: https://www.wjgnet.com/2307-8960/full/v8/i11/2255.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v8.i11.2255